



Pfizer Statement

**POST MARKETING ADVERSE DRUG
EVENT REPORTING REQUIREMENTS**

On June 3, Pfizer Inc. received a Warning Letter from the U.S. Food and Drug Administration, principally concerning the timeliness and categorization of postmarketing adverse drug experience reports. The letter also addressed issues with respect to prescription drug samples. These concerns initially were raised by FDA following an inspection that concluded in August 2009. We will continue to work closely with FDA to address these issues to the Agency's full satisfaction and to assure optimal surveillance and reporting of postmarketing adverse events. We are committed to full compliance and timely and accurate submission of individual adverse event reports. Patient safety is of primary importance to Pfizer, and ensuring the safe and effective use of our medicines is central to our purpose.

Pfizer's product safety system is multifaceted, and individual adverse event reporting is one element of this system. Pfizer believes we provide complete and accurate data to determine the benefit and risk profile for all of our medicines, and to enable their safe and appropriate use. The information necessary to support the safe and effective use of our products is fully disclosed in product labeling, and we stand behind the safety and efficacy of all our products used worldwide.

#

Pfizer Media Contact:
Kristen Neese
(212) 733-8926
(646) 299-2526